View in EDS PDF Full Text

Postmarketing Experience with Topiramate and Cognition.

Saved in:
Bibliographic Details
Title: Postmarketing Experience with Topiramate and Cognition.
Authors: Tatum, W. O., French, J. A., Faught, E., Morris, G. L., Liporace, J., Kanner, A., Goff, S. L., Winters, L., Fix, A.
Source: Epilepsia (Series 4). 2001, Vol. 42 Issue 9, p1134-1140. 7p. 1 Diagram, 2 Charts, 1 Graph.
Subjects: Topiramate, Cognition, Anticonvulsants, Central nervous system diseases
Abstract: Summary: Ideal antiepileptic drugs (AEDs) are designed to stop seizures with limited central nervous system (CNS) side effects. However, CNS-related treatment-emergent adverse events (TEAEs) often occur in patients receiving AEDs. Topiramate (TPM) is an AED proven to be safe and effective as adjunctive treatment for epilepsy patients with partial seizures. Double-blind, placebo-controlled, multicenter trials demonstrated potential effects on cognition. The P.A.D.S. (post-marketing antiepileptic drug survey) group, a cooperative group of 14 epilepsy centers that collaborate on obtaining data about new AEDs and devices, prospectively collected standardized data forms before and during treatment with TPM for epilepsy, and analyzed the postmarketing experience of CNS TEAEs with TPM. Our results from 701 treated patients show that cognitive complaints were the most common reason to discontinue TPM. The presence of complaints did have predictive value if the patient would discontinue TPM, although was not specific as to when discontinuation would occur. The spectrum of complaints in our open-label prospective multicenter postmarketing study was similar to those observed in controlled clinical trials. We were unable to demonstrate a specific population, dose titration, or concomitant AED that was at risk to discontinue treatment. We conclude that most patients treated with TPM will continue therapy beyond 6 months. Cognitive complaints and not efficacy reflect the primary reason for discontinuing therapy. Psychomotor slowing was the most common complaint, yet most patients elect to continue treatment, with “better” or “much better” ratings of both seizure and global improvement during treatment. [ABSTRACT FROM AUTHOR]
Copyright of Epilepsia (Series 4) is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Psychology and Behavioral Sciences Collection
FullText Links:
  – Type: pdflink
Text:
  Availability: 0
Header DbId: pbh
DbLabel: Psychology and Behavioral Sciences Collection
An: 5928307
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Postmarketing Experience with Topiramate and Cognition.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Tatum%2C+W%2E+O%2E%22">Tatum, W. O.</searchLink><br /><searchLink fieldCode="AR" term="%22French%2C+J%2E+A%2E%22">French, J. A.</searchLink><br /><searchLink fieldCode="AR" term="%22Faught%2C+E%2E%22">Faught, E.</searchLink><br /><searchLink fieldCode="AR" term="%22Morris%2C+G%2E+L%2E%22">Morris, G. L.</searchLink><br /><searchLink fieldCode="AR" term="%22Liporace%2C+J%2E%22">Liporace, J.</searchLink><br /><searchLink fieldCode="AR" term="%22Kanner%2C+A%2E%22">Kanner, A.</searchLink><br /><searchLink fieldCode="AR" term="%22Goff%2C+S%2E+L%2E%22">Goff, S. L.</searchLink><br /><searchLink fieldCode="AR" term="%22Winters%2C+L%2E%22">Winters, L.</searchLink><br /><searchLink fieldCode="AR" term="%22Fix%2C+A%2E%22">Fix, A.</searchLink>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22Epilepsia+%28Series+4%29%22">Epilepsia (Series 4)</searchLink>. 2001, Vol. 42 Issue 9, p1134-1140. 7p. 1 Diagram, 2 Charts, 1 Graph.
– Name: Subject
  Label: Subjects
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22Topiramate%22">Topiramate</searchLink><br /><searchLink fieldCode="DE" term="%22Cognition%22">Cognition</searchLink><br /><searchLink fieldCode="DE" term="%22Anticonvulsants%22">Anticonvulsants</searchLink><br /><searchLink fieldCode="DE" term="%22Central+nervous+system+diseases%22">Central nervous system diseases</searchLink>
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: Summary: Ideal antiepileptic drugs (AEDs) are designed to stop seizures with limited central nervous system (CNS) side effects. However, CNS-related treatment-emergent adverse events (TEAEs) often occur in patients receiving AEDs. Topiramate (TPM) is an AED proven to be safe and effective as adjunctive treatment for epilepsy patients with partial seizures. Double-blind, placebo-controlled, multicenter trials demonstrated potential effects on cognition. The P.A.D.S. (post-marketing antiepileptic drug survey) group, a cooperative group of 14 epilepsy centers that collaborate on obtaining data about new AEDs and devices, prospectively collected standardized data forms before and during treatment with TPM for epilepsy, and analyzed the postmarketing experience of CNS TEAEs with TPM. Our results from 701 treated patients show that cognitive complaints were the most common reason to discontinue TPM. The presence of complaints did have predictive value if the patient would discontinue TPM, although was not specific as to when discontinuation would occur. The spectrum of complaints in our open-label prospective multicenter postmarketing study was similar to those observed in controlled clinical trials. We were unable to demonstrate a specific population, dose titration, or concomitant AED that was at risk to discontinue treatment. We conclude that most patients treated with TPM will continue therapy beyond 6 months. Cognitive complaints and not efficacy reflect the primary reason for discontinuing therapy. Psychomotor slowing was the most common complaint, yet most patients elect to continue treatment, with “better” or “much better” ratings of both seizure and global improvement during treatment. [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: <i>Copyright of Epilepsia (Series 4) is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=pbh&AN=5928307
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1046/j.1528-1157.2001.41700.x
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 7
        StartPage: 1134
    Subjects:
      – SubjectFull: Topiramate
        Type: general
      – SubjectFull: Cognition
        Type: general
      – SubjectFull: Anticonvulsants
        Type: general
      – SubjectFull: Central nervous system diseases
        Type: general
    Titles:
      – TitleFull: Postmarketing Experience with Topiramate and Cognition.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Tatum, W. O.
      – PersonEntity:
          Name:
            NameFull: French, J. A.
      – PersonEntity:
          Name:
            NameFull: Faught, E.
      – PersonEntity:
          Name:
            NameFull: Morris, G. L.
      – PersonEntity:
          Name:
            NameFull: Liporace, J.
      – PersonEntity:
          Name:
            NameFull: Kanner, A.
      – PersonEntity:
          Name:
            NameFull: Goff, S. L.
      – PersonEntity:
          Name:
            NameFull: Winters, L.
      – PersonEntity:
          Name:
            NameFull: Fix, A.
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 09
              Text: 2001
              Type: published
              Y: 2001
          Identifiers:
            – Type: issn-print
              Value: 00139580
          Numbering:
            – Type: volume
              Value: 42
            – Type: issue
              Value: 9
          Titles:
            – TitleFull: Epilepsia (Series 4)
              Type: main
ResultId 1